Released Aug 13, 2025, after the close
10-Q filed Aug 13, 2025, 44 days after period end · 0001493152-25-011910
Q2 2025 · 10-Q
Revenue—
Net Income-$3.14M-$3.14M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$15.19-$15.19 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$2,501,000N/M
Operating Cash Flowderived-$2,532,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | — | $47.00K | — | — |
| Net Income | -$3.14M | -$5.53M | -$4.51M | -$3.40M |
| EPS Diluted | -$15.19 | -$15.34 | -$0.85 | -$1.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR